Liver Disease Therapeutics Market Evolves with Smart Biotech

Liver Disease Therapeutics Market Size, Shares and Insights with Top Key Players

The global liver disease therapeutics market size is calculated at US$ 26.54 billion in 2025, grew to US$ 27.99 billion in 2026, and is projected to reach around US$ 45.25 billion by 2035. The market is expanding at a CAGR of 5.48% between 2026 and 2035.

The rapid aging of the world's population, shifting lifestyles, government and non-governmental organization awareness campaigns, the rise in unhealthy fast food consumption, and increased investment in R&D all contributed to the growth of the global liver disease therapeutics market. The market is expanding due to technological developments in liver disease diagnosis, such as imaging methods, liver function tests, and biomarker-based diagnostics.

Key Takeaways

• Liver disease therapeutics sector pushed the market to USD 26.54 billion by 2025.
• Long-term projections show USD 45.25 billion valuation by 2035.
• Growth is expected at a steady CAGR of 5.48% in between 2026 to 2035.
• North America dominated the liver disease therapeutics market in 2024, with a revenue of approximately 40%.
• Asia Pacific is expected to be the fastest-growing region during the forecast period.
• By indication, the viral hepatitis (HBV & HCV) segment dominated the market in 2024, with a revenue of approximately 38%.
• By indication, the non-alcoholic fatty liver disease/NASH segment is expected to be the fastest-growing during the forecast period.
• By therapy type/mechanism, the antivirals segment dominated the market in 2024, with a revenue of approximately 35%.
• By therapy type/mechanism, the antifibrotics/metabolic agents segment is expected to be the fastest-growing during the forecast period.
• By modality/drug class, the small-molecule therapeutics segment dominated the liver disease therapeutics market in 2024, with a revenue of approximately 60%.
• By modality/drug class, the biologics & monoclonal antibodies segment is expected to be the fastest-growing during the forecast period.
• By route of administration/dosage form, the oral segment dominated the market in 2024, with a revenue of approximately 68%.
• By route of administration/dosage form, the injectable/infusible segment is expected to be the fastest-growing during the forecast period.
• By end-user/care setting, the hospitals & tertiary care centers segment dominated the liver disease therapeutics market in 2024.
• By end-user/care setting, the oncology centers segment is expected to be the fastest-growing during the forecast period.

Quick Facts Table

Rising Liver Diseases: Making the Market Grow Exponentially

The liver disease therapeutics market is driven by global burdens of viral hepatitis and metabolic-associated liver disease, advances in antiviral cures and novel antifibrotic/ metabolic candidates, growing diagnostics and patient awareness, and rising investment into NASH and HCC therapeutics. The market comprises pharmaceuticals, biologics, advanced cell and gene therapies, and supportive care products used to prevent, treat, manage, or slow the progression of liver diseases. Key indications include viral hepatitis (HBV, HCV), non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma (HCC), and autoimmune and cholestatic liver diseases.

Every year, liver disease kills more than two million people worldwide. The prevalence of metabolic-associated steatotic liver disease (MASLD) is expected to rise dramatically by 2030 in many areas, contributing to the growing burden of MASLD in 2024. Deaths from viral hepatitis (HBV/HCV) are also a serious concern; by 2030, the WHO wants to reduce mortality by 65%.

Liver Disease Therapeutics Market Outlook

• Industry Growth Overview: Because diseases like hepatitis and non-alcoholic fatty liver disease are becoming more common, the market is growing. The aging of the world's population and growing awareness of the need for early detection and treatment of chronic liver diseases are major motivators. Biotechnological developments like gene editing and regenerative medicine are also influencing product development and speeding up market growth.
• Major Investors: The liver disease therapeutics market is dominated by large biopharmaceutical firms such as Bristol-Myers Squibb, AbbVie, Gilead Sciences, and Merck & Co. Significant investment in treatments for metabolic liver disease has been highlighted by recent M&A activity, with major agreements from Novo Nordisk, GSK, and Roche concentrating on cutting-edge treatments like FGF21 agonists.
• Startup Ecosystem: Precision medicine and targeted therapies are the focus of a thriving startup ecosystem that includes businesses like Akero Therapeutics and Madrigal Pharmaceuticals. Venture capital investments are on the rise, especially for early-stage businesses creating RNA-based therapies, AI-powered diagnostics, and anti-fibrotic drugs for diseases like NASH.

What is the Role of AI in the Liver Disease Therapeutics Market?

The hallmark of clinical care in hepatology is the ability to identify patterns in laboratory data and clinical features. Large language models and machine learning or deep learning are examples of artificial intelligence (AI) tools that offer intriguing ways to support the advancement of care. AI tools offer the chance to replicate the clinician's unconscious decision-making processes and train on large amounts of data.

Segmental Insights

Indication Insights

Which Indication Dominated the Market in 2024?

The viral hepatitis (HBV & HCV) segment led the liver disease therapeutics market in 2024, accounting for approximately 38% of revenue. The World Health Organization's (WHO) 2024 Global Hepatitis Report states that viral hepatitis is becoming a greater cause of death. With 1.3 million deaths annually, the illness is the second most common infectious cause of death worldwide, ranking on par with tuberculosis, which is the leading infectious killer.

Non-Alcoholic Fatty Liver Disease/NASH

The non-alcoholic fatty liver disease/NASH segment is anticipated to showcase the highest CAGR during the studied period. Nearly 30% of people worldwide suffer from nonalcoholic fatty liver disease (NAFLD), a condition that is becoming more prevalent as other metabolic diseases are. NAFLD is extremely common, especially in nations with lower HDI. There is a considerable risk that these people will develop end-stage liver disease due to the continuous rise in adult and pediatric obesity rates worldwide, especially when coexisting NAFLD is present.

Cirrhosis

The cirrhosis segment is growing significantly in the market. Cirrhosis, liver cancer, and other liver disorders are examples of chronic liver diseases (CLD), which continue to be a major global public health concern. They contribute significantly to the burden of mortality, morbidity, and medical expenses.

Therapy Type/Mechanism Insights

Why were Antivirals Dominant in the Market in 2024?

The antivirals segment led the liver disease therapeutics market in 2024, accounting for approximately 35% of revenue. Numerous antiviral medications can combat the virus and lessen its capacity to harm your liver. These medications include adefovir (Hepsera), lamivudine (Epivir), tenofovir (Viread), and entecavir (Baraclude).

Antifibrotics/Metabolic Agents

The antifibrotics/metabolic agents segment is anticipated to showcase the highest CAGR during the studied period. There are very few effective treatment options for fibrosis, a common pathological process that can affect almost all of the organs. Over the past few decades, this has sparked a fierce hunt for antifibrotic treatments, and numerous clinical tests are now being conducted.

Immunomodulators & Checkpoint Inhibitors

The immunomodulators & checkpoint inhibitors segment is growing significantly in the liver disease therapeutics market. Hepatocellular (HCC) and biliary tract cancer are among the cancers for which immune checkpoint inhibitors (ICI) have produced ground-breaking advancements in treatment, raising patient survival and enhancing long-standing standards of care.

Modality/Drug Class Insights

Why Small-Molecule Therapeutics Dominated the Market in 2024?

The small-molecule therapeutics segment led the liver disease therapeutics market in 2024, accounting for approximately 60% of revenue. Current clinical guidelines from the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network strongly recommend small-molecule-based targeted therapies (first line: sorafenib and lenvatinib; second line: regorafenib and cabozantinib).

Biologics & Monoclonal Antibodies

The biologics & monoclonal antibodies segment is anticipated to showcase the highest CAGR during the studied period. Because they specifically target underlying mechanisms like inflammation and fibrosis, biologics and monoclonal antibodies are essential in the treatment of liver disease. For ailments like primary biliary cholangitis and autoimmune hepatitis, they provide hope by possibly delaying the course of the illness and enhancing results.

Cell Therapies/Regenerative Approaches

The cell therapies/regenerative approaches segment is growing significantly in the liver disease therapeutics market. Cell-based regenerative therapies employing functional hepatocyte-like cells derived from pluripotent stem cells are being investigated in an effort to create more effective treatments for chronic liver diseases. Thus, it is anticipated that the next generation of regenerative therapies will be cell-based ones that use newly generated or expanded hepatocytes in vitro.

Route Of Administration/Dosage Form Insights

Why was the Oral Segment Dominant in the Market in 2024?

The oral segment led the liver disease therapeutics market in 2024, accounting for approximately 68% of revenue. Significant patient-centric benefits like convenience, ease, and non-invasiveness make oral medications popular for liver disease because they increase patient adherence to long-term treatment plans.

Injectable/Infusible

The injectable/infusible segment is anticipated to showcase the highest CAGR during the studied period. An increasingly popular supportive treatment for liver disease is intravenous therapy. It guarantees quick absorption of vital substances by avoiding the digestive system. IV therapy is given by medical professionals to improve liver function and reduce symptoms.

Topical/Local

The topical/local segment is growing significantly in the liver disease therapeutics market. In order to minimize systemic exposure and lower the risk of adverse effects in other organs, topical/local medications for liver disease, which frequently employ sophisticated delivery systems, are recommended.

End-User/Care Setting Insights

Which End-User Dominated the Market in 2024?

The hospitals & tertiary care centers segment led the liver disease therapeutics market in 2024. Because they have access to cutting-edge technology, interdisciplinary specialist teams, and comprehensive care facilities that can handle complicated procedures like liver transplants, hospitals are the preferred option for treating liver disease.

Oncology Centers

The oncology centers segment is anticipated to showcase the highest CAGR during the studied period. Oncology centers such as HCG Manavata Cancer Centre in Nashik, Rajiv Gandhi Cancer Institute & Research Centre (Delhi), and Max Healthcare provide specialized care for liver disease and cancer with advanced therapies like Transarterial Chemoembolization (TACE), chemotherapy, and surgical options like liver resection and transplant. The Cleveland Clinic, Manipal Hospitals, and the Mayo Clinic are other top institutions with liver cancer programs.

Specialist Clinics/Gastroenterology & Hepatology Centers

The specialist clinics/gastroenterology & hepatology centers segment is growing significantly in the market. Prominent international centers for gastroenterology, hepatology, and liver disease treatment are well-known for their multidisciplinary expertise, high success rates, and cutting-edge technology.

Regional Insights

North America’s Advanced Healthcare System is a Major Market Driver

North America dominated the liver disease therapeutics market in 2024. The area is known for its advanced medical facilities, high healthcare expenditures, and sizable concentration of well-known biotechnology and pharmaceutical firms. Due to the high incidence of liver diseases in the area, including hepatitis, liver cancer, and non-alcoholic fatty liver disease (NAFLD), there is a significant need for efficient treatments.

Chronic HVC: A Growing Health Burden in the U.S.

About 4,000,000 people in the US are seropositive for HCV, and 270K have a chronic infection, making HCV the most common blood-borne viral disease in the country. In the U.S., 74% of HCV patients have Genotype 1, which has the lowest response rate (up to 50%) to the only medications the FDA has approved to treat it: pegylated interferon with ribavirin. Patients with chronic HCV are the recipients of about half of liver transplants in the U.S.

Why is the Market Expected to Grow Rapidly in the Asia Pacific?

Asia Pacific is estimated to host the fastest-growing liver disease therapeutics market during the forecast period. A high burden of viral hepatitis is present in countries like China, India, and Southeast Asia because of their large populations and rapidly rising incidence of liver diseases, particularly hepatitis B and C. These countries' low vaccination rates over decades, poor sanitation in some areas, and vertical virus transmission are some of the contributing factors.

Liver Disease Epidemic in India: Poor Diet & Health Choices are the Main Causes

Current estimates place the annual number of liver disease deaths in India at about 268,580, or 3.17% of all deaths in the nation. More startlingly, this amounts to 18.3% of liver-related deaths worldwide, placing India as the leading cause of liver disease deaths globally. Fatty liver disease, hepatitis infections, alcohol-induced liver damage, and metabolic disorders linked to lifestyle choices are the main causes of liver disease in India. A poor diet, which is frequently heavy in processed foods, sugar, and unhealthy fats, is a major contributing factor.

High Alcohol Consumption Driving the Market in Europe

Europe is expected to grow at a significant CAGR in the liver disease therapeutics market during the forecast period, caused by aging populations, widespread alcohol use, and the growing prevalence of liver cancer, NAFLD, and hepatitis. National screening programs and increased public health awareness have led to higher early diagnosis rates in the region. Centralized healthcare systems and increased reimbursement coverage are improving access to cutting-edge treatments, such as DAAs and innovative targeted therapies.

Growing Liver Disease-Related Research in the UK

Since liver disease is becoming more common in the UK, scientific research into early detection and treatment is more important than ever in order to combat the steadily rising death rate. In the UK, liver disease is predicted to surpass heart disease as the leading cause of premature death, despite the fact that 90% of it is preventable. In Western Europe, the UK currently has one of the highest mortality rates from liver disease.

South America’s Healing Horizon

South America is expected to grow significantly in the liver disease therapeutics market during the forecast period.     Consumers and clinicians drive liver therapeutics innovation as diagnostics and access expand across urban centers. Governments and funds support clinical trials and care models, boosting demand for novel treatments and integrated patient management across emerging healthcare landscapes.

Brazil’s Breakthrough Beat

Homegrown research and private capital accelerate liver therapeutics development with expanding trial sites and specialised centers. Rising metabolic disease drives treatment innovation, as the ELSA Brasil study found hepatic steatosis prevalence of 35.1% among adults, underscoring urgent clinical needs.

MEA’s Expanding Pulse

The Middle East and Africa are expected to grow at a lucrative CAGR in the liver disease therapeutics market during the forecast period. Urbanisation and rising obesity propel liver therapeutics interest as healthcare systems expand diagnostics and specialist care. Governments, partners, and industry invest in capacity, regional trials, and workforce development, opening pathways for novel therapies and integrated chronic disease management.

UAE’s Wellness Revolution

High incomes and healthcare sophistication position the UAE as a premium market for liver therapeutics and personalised care. Projections estimate 372,000 NAFLD cases by 2030 in the UAE, fuelling investment in diagnostics, specialty clinics, and advanced treatment options.

Liver Disease Therapeutics Market Value Chain Analysis

R&D

The standard, stringent drug development pipeline, which usually takes more than ten years and consists of five primary stages regulated by organizations like the FDA, is followed in the research and development (R&D) steps for liver disease therapeutics.

• Key Players include Gilead Sciences, AbbVie, Novo Nordisk, AstraZeneca, Pfizer, and Roche.

Clinical Trials and Regulatory Approvals

Preclinical studies and an IND application are necessary for the development of a treatment for liver disease. Phases 1 (safety), 2 (efficacy/side effects), and 3 (large-scale confirmation) are the stages of clinical trials. A New Drug Application (NDA) and regulatory review (FDA Drug Review) follow from this. Phase 4 measures long-term safety after the product is put on the market.

• Key players include Gilead Sciences, AbbVie, Novo Nordisk, AstraZeneca, Pfizer, and Roche.

Patient Support and Services

Liver disease patient support and services include medical, financial, and emotional resources offered by government agencies, non-profits, and healthcare systems to assist in managing the illness and navigating available treatments.

• Key players include Gilead Sciences, AbbVie, Novo Nordisk, AstraZeneca, Pfizer, and Roche.

Company Landscape

Gilead Sciences

Company Overview:

• A research-based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in areas of unmet medical need.
• Pioneered transformative treatments for HIV, viral hepatitis (HCV, HBV, HDV), and is expanding into oncology and inflammation.
• Its HCV portfolio, featuring pan-genotypic, short-duration regimens, has been a major market driver in liver disease therapeutics.

Corporate Information (Headquarters, Year Founded, Ownership Type):

• Headquarters: Foster City, California, United States
• Year Founded: 1987
• Ownership Type: Public (NASDAQ: GILD)

History and Background:

• Established a foundation in antiviral drugs, notably with HIV treatments like Viread (tenofovir disoproxil fumarate).
• Achieved market dominance in HCV with the introduction of Direct-Acting Antivirals (DAAs) like Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), which revolutionized treatment with high cure rates.

Key Milestones/Timeline:

• 2013: FDA approval of Sovaldi (sofosbuvir), initiating the DAA era for HCV.
• 2014: FDA approval of Harvoni (ledipasvir/sofosbuvir), the first single-pill regimen for most HCV patients.
• 2016: FDA approval of Epclusa (sofosbuvir/velpatasvir), the first pangenotypic HCV treatment.
• 2024: Continues to advance its Hepatitis B (HBV) and Hepatitis D (HDV) pipeline programs.

Business Overview:

• Mission: To create a healthier world by advancing and applying science globally.
• Focus Areas: Antivirals (HIV, Viral Hepatitis), Oncology, Inflammatory/Fibrotic Diseases.
• 2024 Revenue: Remains one of the top biopharma companies globally, with significant revenue from its Virology and Oncology segments.

Business Segments/Divisions:

• Virology: Focuses on HIV, Hepatitis B, C, and D.
• Oncology: Developing treatments for various cancers, including liver cancer (Hepatocellular Carcinoma - HCC).
• Cell Therapy: Focused on CAR T-cell therapies (through Kite Pharma subsidiary).

Geographic Presence:

• Global operations, with products sold in over 100 countries.
• Major revenue sources in the United States and Europe.

Key Offerings:

• Hepatitis C (HCV): Epclusa, Harvoni, Vosevi, Sovaldi.
• Hepatitis B (HBV): Vemlidy, Viread.
• Hepatitis D (HDV): Hepcludex (bulevirtide) in certain regions (acquired through the acquisition of MYR Pharmaceuticals).
• Oncology: Expanding portfolio, including treatments relevant to liver cancer.

End-Use Industries Served:

• Hospitals and Clinics
• Retail and Specialty Pharmacies
• Government Programs (e.g., in HIV/HCV elimination efforts)

Key Developments and Strategic Initiatives:

• Mergers & Acquisitions:
  • 2020-2024: Focus on strengthening the oncology pipeline (e.g., Immunomedics acquisition).
  • 2020: Acquisition of MYR Pharmaceuticals to secure Hepcludex (bulevirtide) for HDV.
• Partnerships & Collaborations:
  • Ongoing collaborations for research into HBV functional cure and MASH/NASH treatments.
  • Partnerships for global access programs for HIV and viral hepatitis drugs in developing countries.
• Product Launches/Innovations:
  • Continuous development of next-generation antivirals and long-acting treatments.
  • Advancing pipeline candidates for MASH/NASH.

Capacity Expansions/Investments:

Significant R&D investment of over $5 billion in 2024 (estimated) across its therapeutic areas.

Regulatory Approvals:

• Seeking broader indications and new formulations for existing core products.
• Advancing its oncology pipeline with new regulatory filings.

Distribution channel strategy:

• Leveraging specialty pharmacies and hospital distribution networks due to the high-cost, specialized nature of its therapies (especially HCV and oncology).
• Strong focus on patient access programs to mitigate cost barriers.

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Strong patent portfolio in antivirals, particularly in nucleotide/nucleoside analogs (e.g., tenofovir, sofosbuvir derivatives).
• Research & Development Infrastructure: Global R&D centers dedicated to small molecule and biologic drug discovery, virology, and translational medicine.

Innovation Focus Areas:

• Functional cure for Chronic Hepatitis B (HBV).
• Novel therapies for MASH/NASH and advanced liver fibrosis.
• Expanding the oncology portfolio into solid tumors, including HCC.

Competitive Positioning:

• Strengths & Differentiators:
  • Market Leadership in HCV: Unparalleled history and high-efficacy treatments in hepatitis C.
  • Deep Virology Expertise: Strong foundation in complex antiviral drug development (HIV, HBV, HDV).
  • Robust Financials: High cash flow supporting extensive R&D and strategic M&A.
• Market presence & ecosystem role:
  • Dominant player in the global infectious disease market.
  • Key role in global public health initiatives for viral hepatitis and HIV eradication.

SWOT Analysis:

• Strengths: Dominant position in HCV; strong HIV/Antiviral franchise; deep R&D capabilities.
• Weaknesses: Declining HCV revenue post-peak due to high cure rates and market maturity; patent expiry challenges for some core assets.
• Opportunities: MASH/NASH pipeline development; HBV functional cure; Oncology expansion (including HCC).
• Threats: Increased competition in MASH/NASH; pricing pressure on mature products; successful generic entry for some antivirals.

Recent News and Updates (2024-2025):

• Press Releases:
• • Mid-2025: Announced positive Phase 2 data for a key MASH/NASH pipeline asset, demonstrating significant anti-fibrotic activity.
  • Early 2024: Reported significant progress in its clinical trial programs for functional cure of chronic Hepatitis B (HBV).
  • Industry Recognitions/Awards: Consistently recognized for its global health contribution in infectious diseases.

AbbVie Inc.

Company Overview:

• A global, research-based biopharmaceutical company committed to developing innovative advanced therapies.
• Major therapeutic areas include immunology, oncology, neuroscience, eye care, and virology (historically strong in Hepatitis C).
• Its HCV treatment, Mavyret, remains a key pan-genotypic option in the market.

Corporate Information (Headquarters, Year Founded, Ownership Type):

• Headquarters: North Chicago, Illinois, United States
• Year Founded: 2013 (Spun off from Abbott Laboratories)
• Ownership Type: Public (NYSE: ABBV)

History and Background:

• Formed as the research-based pharmaceutical company when Abbott Laboratories split into two publicly traded companies in 2013.
• Inherited a strong R&D foundation and focused on building a specialized portfolio.
• Became a major force in the HCV market with the development and launch of Viekira Pak and later the highly effective, pan-genotypic regimen, Mavyret.

Key Milestones/Timeline:

• 2013: Spin-off from Abbott Laboratories.
• 2014: FDA approval of Viekira Pak for HCV.
• 2017: FDA approval of Mavyret (glecaprevir/pibrentasvir), a pan-genotypic, 8-week treatment for most HCV patients.
• 2024-2025: Strategic focus on growing Immunology and Oncology, while maintaining a strong virology presence.

Business Overview:

• Mission: To discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.
• Focus Areas: Immunology, Oncology, Neuroscience, Aesthetics (Allergan Aesthetics), and Virology.
• 2024 Revenue: Reported total annual revenue of approximately $56.33 billion (2024 estimate/report).

Business Segments/Divisions:

• Immunology: (e.g., Humira, Skyrizi, Rinvoq).
• Oncology: (e.g., Imbruvica, Venclexta).
• Neuroscience.
• Allergan Aesthetics.
• Virology: Includes the HCV franchise.

Geographic Presence:

• Operates in over 175 countries worldwide.
• Significant sales and R&D activities across North America, Europe, and Asia.

Key Offerings:

• Hepatitis C (HCV): Mavyret (glecaprevir/pibrentasvir) - a leading short-course, pan-genotypic treatment.
• Infectious Diseases: EMBLAVEO (aztreonam and avibactam) for complicated intra-abdominal infections (February 2025 US approval).
• Oncology: Products used in blood cancers, which can be relevant for patients with liver disease complications.

End-Use Industries Served:

• Hospitals and Specialty Clinics
• Ambulatory Surgical Centers
• Specialty and Retail Pharmacies

Key Developments and Strategic Initiatives:

Mergers & Acquisitions:

2024: Acquisition of Landos Biopharma (March 2024) and Cerevel Therapeutics (August 2024) to expand the pipeline in immunology and neuroscience, respectively.

Partnerships & Collaborations:

• Active partnerships for global access to its HCV medicines.
• Collaborations in early-stage research in oncology and immunology, including with Tentarix Biotherapeutics (February 2024).

Product Launches/Innovations:

• Continued focus on immunology and oncology pipeline candidates.
• EMBLAVEO approval (Feb 2025) for cIAI, reflecting its infectious disease strength.

Capacity Expansions/Investments:

• R&D investment of $10.8 billion in 2024.
• Strategic investments in manufacturing and supply chain to support blockbuster products.

Regulatory Approvals:

• February 2025: U.S. FDA approval of EMBLAVEO for complicated intra-abdominal infections (cIAI).
• Advancing late-stage pipeline programs, particularly in immunology and oncology.

Distribution channel strategy:

Utilizes a mix of specialized distribution channels for its HCV and oncology products, ensuring precise patient reach and adherence support.

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Strong intellectual property surrounding its DAA combinations (Mavyret) and various biologic therapies (e.g., anti-IL-23, JAK inhibitors).
• Research & Development Infrastructure: Focused R&D in small molecules, biologics, and immunology, with a pipeline of nearly 90 compounds/indications.

Innovation Focus Areas:

• Next-generation immunology and oncology therapies.
• Early-stage development in MASH/MASLD, including a dual agonist of GLP-1 and glucagon receptors.
• Virology pipeline maintenance and exploration of new infectious disease areas.

Competitive Positioning:

• Strengths & Differentiators:
  • HCV Cure Rate: Mavyret provides a leading, highly effective, short-duration (8-week) treatment option.
  • Diversified Portfolio: Strong foundation outside of virology (Immunology and Oncology) provides revenue stability.
  • R&D Investment: Substantial annual R&D spend fuels a robust pipeline.
• Market presence & ecosystem role:
  • A top-tier global biopharmaceutical company with a major presence in chronic disease management.
  • Critical competitor in the viral hepatitis segment, driving access and affordability.

SWOT Analysis:

• Strengths: Strong cash flow; high-efficacy, short-course HCV treatment (Mavyret); diversified, growing portfolio (Immunology, Oncology).
• Weaknesses: High reliance on core immunology product (Humira biosimilar erosion challenge); less focused on emerging HBV/HDV cure segments compared to Gilead.
• Opportunities: Success in MASH/MASLD pipeline; oncology expansion; leveraging acquired assets (e.g., Cerevel, Landos).
• Threats: Intense competition in HCV from Gilead; biosimilar market entry impacting legacy products; clinical trial attrition in new focus areas.

Recent News and Updates (2024-2025):

• Press Releases:
  • February 2025: Announced FDA approval of EMBLAVEO for complicated intra-abdominal infections.
  • July 2025: Submitted for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated CLL.
  • Industry Recognitions/Awards: Named a top workplace for various metrics, including diversity and inclusion, in 2024.

Top Vendors in the Liver Disease Therapeutics Market & Their Offerings

Top Companies in the Liver Disease Therapeutics Market

• Gilead Sciences
• AbbVie
• Merck & Co.
• Roche/Genentech
• Bristol-Myers Squibb (BMS)
• Novartis
• Johnson & Johnson (Janssen)
• Pfizer
• Sanofi
• Takeda Pharmaceutical
• Intercept Pharmaceuticals
• Madrigal Pharmaceuticals
• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Medivation / Astellas
• Eli Lilly
• Novo Nordisk
• Galmed Pharmaceuticals / Other biotech (representative)
• Vertex Pharmaceuticals

Explore further to see how top players are transforming the Liver Disease Therapeutics Market at: https://www.towardshealthcare.com/companies/liver-disease-therapeutics-companies

Recent Developments in the Liver Disease Therapeutics Market

• In July 2025, to prevent, test for, treat, and cure Hepatitis C (HCV) in people with substance use disorder (SUD) and/or serious mental illness (SMI), the U.S. Department of Health and Human Services (HHS) announced a $100 million pilot funding opportunity. 
• In June 2025, to further the development of AHB-137, a treatment for chronic hepatitis B, AusperBio raised $50 million. According to the company, the money will be used to invest in its expanding pipeline, expand manufacturing partnerships, and initiate Phase 2 clinical trials outside mainland China.
• In May 2025, a S$9 million investment round closed to support HistoIndex's next phase of growth. The company is well-known for its innovative biophotonic Second Harmonic Generation (SHG) technology and is a trailblazing leader in Artificial Intelligence (AI) digital pathology for the treatment of fibrotic diseases.
• In April 2025, Ideaspring Capital is leading a $1.25 million Pre-Series A funding round for Chennai-based molecular diagnostics startup Tvaster Genkalp. Episcreen™ Liver, a ground-breaking methylation-based liquid biopsy test intended for the early detection of liver cancer, will be commercialized and expanded throughout India with the help of the recently raised funds.

Segments Covered in the Report

By Indication

• Viral Hepatitis (HBV & HCV)
• Non-Alcoholic Fatty Liver Disease/NASH
• Cirrhosis (complications management)
• Hepatocellular Carcinoma (HCC)
• Autoimmune & Cholestatic Liver Diseases (e.g., PBC, PSC)
• Other (alcohol-related liver disease, rare metabolic liver disorders)

By Therapy Type/Mechanism

• Antivirals
• Antifibrotics/Metabolic Agents
• Immunomodulators & Checkpoint Inhibitors
• Targeted Oncology Therapies (for HCC)
• Supportive/Symptomatic Agents (ascites diuretics, portal hypertension drugs)
• Advanced Therapies (cell therapy, gene editing)

By Modality/Drug Class

• Small-Molecule Therapeutics
• Biologics & Monoclonal Antibodies
• RNAi/Antisense/Gene Therapies
• Cell Therapies/Regenerative Approaches

By Route of Administration/Dosage Form

• Oral
• Injectable/Infusible (including monoclonals, IV oncology agents)
• Topical/Local (limited)
• Advanced delivery (gene vectors, cell infusions)

By End-User/Care Setting

• Hospitals & Tertiary Care Centers
• Specialist Clinics/Gastroenterology & Hepatology Centers
• Ambulatory/Primary Care (screening & stable chronic therapy)
• Oncology Centers (HCC)
• Homecare/Outpatient Infusion (growing for some injectables)

By Region

• North America
  • U.S. 
  • Canada 
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe
  • Austria
  • Russia & Belarus
  • Türkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA 
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt 
• Rest of MEA